Shield Therapeutics PLC Block listing Interim Return (4420O)
October 03 2023 - 1:00AM
UK Regulatory
TIDMSTX
RNS Number : 4420O
Shield Therapeutics PLC
03 October 2023
Shield Therapeutics plc
("Shield" or the "Company" or the "Group")
Block Listing 6 Monthly Return
Name of applicant: SHIELD THERAPEUTICS PLC
Name of scheme: Shield Therapeutics Retention Share Plan
---------------------------------------------
Period of return: From: 31 March 2023 To: 30 September 2023
------------------------ ---------------- ----- --------------------
Balance of unallotted securities under scheme(s) from previous return: 39,794
---------------------------------------------
Plus: The amount by which the block scheme(s) has been increased since NIL
the date of the last
return (if any increase has been applied for):
---------------------------------------------
Less: Number of securities issued/allotted under scheme(s) during NIL
period (see LR3.5.7G):
---------------------------------------------
Equals: Balance under scheme(s) not yet issued/allotted at end of
period: 39,794
---------------------------------------------
Name of applicant: SHIELD THERAPEUTICS PLC
Name of scheme: Shield Therapeutics plc 2016 Company Share Option Plan
-----------------------------------------------------------
Period of return: From: 31 March 2023 To: 30 September 2023
------------------------ ---------------------- ------ ---------------------------
Balance of unallotted securities under scheme(s) from
previous return: 341,020
-----------------------------------------------------------
Plus: The amount by which the block scheme(s) has been NIL
increased since the date of the last
return (if any increase has been applied for):
-----------------------------------------------------------
Less: Number of securities issued/allotted under NIL
scheme(s) during period (see LR3.5.7G):
-----------------------------------------------------------
Equals: Balance under scheme(s) not yet issued/allotted
at end of period: 341,020
-----------------------------------------------------------
Name of applicant: SHIELD THERAPEUTICS PLC
Name of scheme: The Shield Therapeutics plc 2016 Long Term Incentive Plan
-------------------------------------------------------------
Period of return: From: 31 March 2023 To: 30 September 2023
------------------------ ----------------------- ------ ----------------------------
Balance of unallotted securities under scheme(s) from
previous return: 24,273
-------------------------------------------------------------
Plus: The amount by which the block scheme(s) has been NIL
increased since the date of the last
return (if any increase has been applied for):
-------------------------------------------------------------
Less: Number of securities issued/allotted under NIL
scheme(s) during period (see LR3.5.7G):
-------------------------------------------------------------
Equals: Balance under scheme(s) not yet
issued/allotted at end of period: 24,273
-------------------------------------------------------------
Name of applicant: SHIELD THERAPEUTICS PLC
Name of scheme: Shield Therapeutics Retention and Performance Share Plan
-------------------------------------------------------------
Period of return: From: 31 March 2023 To: 30 September 2023
------------------------ ----------------------- ------ ----------------------------
Balance of unallotted securities under scheme(s) from
previous return: 2,870,838
-------------------------------------------------------------
Plus: The amount by which the block scheme(s) has been NIL
increased since the date of the last
return (if any increase has been applied for):
-------------------------------------------------------------
Less: Number of securities issued/allotted under NIL
scheme(s) during period (see LR3.5.7G):
-------------------------------------------------------------
Equals: Balance under scheme(s) not yet
issued/allotted at end of period: 2,870,838
-------------------------------------------------------------
Name of contact: Lucy Huntington-Bailey
Telephone number of contact: +44 (0) 191 511 8500
-----------------------
For further information please contact:
Shield Therapeutics plc www.shieldtherapeutics.com
Greg Madison, CEO +44 (0) 191 511 8500
Hans-Peter Rudolf, CFO
Nominated Adviser and Joint
Broker
Peel Hunt LLP
James Steel/Patrick Birkholm +44 (0)20 7418 8900
Joint Broker
Cavendish Capital Markets Ltd
Geoff Nash/ George Dollemore/Nigel
Birks/Harriet Ward +44 (0)20 7220 0500
Financial PR & IR Advisor
Walbrook PR
Lianne Applegarth/Alice Woodings +44 (0)20 7933 8780 or shield@walbrookpr.com
Investor Contact (US Advisor) +1 617 429 3548 or jmullaly@lifesciadvisors.com
LifeSci Advisors, LLC
John Mullaly
About Accrufer(R)/Feraccru(R)
Accrufer(R)/Feraccru(R) (ferric maltol) is a novel, stable,
non-salt based oral therapy for adults with iron deficiency, with
or without anemia. Accrufer(R)/Feraccru(R) has a novel mechanism of
action compared to other oral iron therapies and has been shown to
be an efficacious and well-tolerated therapy in a range of clinical
trials. More information about Accrufer(R)/Feraccru(R), including
the product label, can be found at: www.accrufer.com and
www.feraccru.com
About Shield Therapeutics plc
Shield is a commercial stage specialty pharmaceutical company
with a focus on addressing iron deficiency with its lead product
Accrufer(R)/Feraccru(R) (ferric maltol). The Group has launched
Accrufer(R) in the US and Feraccru(R) is commercialized in the UK
and European Union by Norgine B.V., who also have the marketing
rights in Australia and New Zealand. Shield also has an exclusive
license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd.,
for the development and commercialization of Accrufer(R) /
Feraccru(R) in China, Hong Kong, Macau and Taiwan, with Korea
Pharma Co., Ltd. in the Republic of Korea, and with KYE
Pharmaceuticals Inc. in Canada.
Accrufer(R)/Feraccru(R) has patent coverage until the
mid-2030s
Accrufer(R)/Feraccru(R) are registered trademarks of the Shield
Group
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BLRDZMGGNZNGFZM
(END) Dow Jones Newswires
October 03, 2023 02:00 ET (06:00 GMT)
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Apr 2023 to Apr 2024
